4D Molecular Therapeutics, Inc. Common Stock Profile
About
4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
Info & Links
CEO
David Kirn
Headquarters
5858 HORTON STREET #455 EMERYVILLE, CA 94608, UNITED STATES
4D Molecular Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
137.75M
Enterprise Value
-11.59M
Enterprise Value/EBITDA(ttm)
0.06
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.44
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
75.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
-569052.72%
Return on Equity(ttm)
-28.00%
Return on Invested Capital(ttm)
-28.99%
Return on Assets(ttm)
-26.16%
Income Statement
Revenue(ttm)
37.00K
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
37.00K
EBITDA(ttm)3
-190.37M
Net Income Available to Common(ttm)
-160.87M
Diluted EPS(ttm)
-2.85
Share Statistics
Beta (5Y Monthly)
2.81
52-Week Change
-87.94%
S&P 500 52-Week Change
5.42%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
46.30M
Dividend Yield
0.00%
Float4
42.85M
% Held by Insiders
7.30%
% Held by Institutions
99.27%
Balance Sheet
Total Cash(mrq)
424.88M
Total Cash Per Share(mrq)
9.18
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
14.92%
Quick Ratio(mrq)
17.33%
Book Value Per Share(mrq)
11.15
Cash Flow
Operating Cash Flow Per Share(ytd)
-2.49
Free Cash Flow(ytd)
-138.37M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.